

(51) International Patent Classification:
G01N 33/68 (2006.01)(21) International Application Number:
PCT/US2021/044761(22) International Filing Date:
05 August 2021 (05.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/062,243 06 August 2020 (06.08.2020) US(71) Applicant: **BIOVERATIV USA INC.** [US/US]; 225 Second Avenue, Waltham, MA 02451 (US).(72) Inventors: **ARIAS, Jaime, Morales**; 225 Second Avenue, Waltham, MA 02451 (US). **HOBBS, William, E.**; 225 Second Avenue, Waltham, MA 02451 (US). **STOREK, Michael, J.**; 225 Second Avenue, Waltham, MA 02451 (US). **PATEL, Parija, S.**; 225 Second Avenue, Waltham, MA 02451 (US).(74) Agent: **CHIMALAKONDA, Gitanjali** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: INFLAMMATORY CYTOKINES AND FATIGUE IN SUBJECT WITH A COMPLEMENT MEDIATED DISEASE




FIG. 1

(57) Abstract: Provided herein are methods for treating complement-mediated diseases such as cold agglutinin disease (CAD) and associated conditions such as fatigue using anti-C1s antibodies such as sutimlimab, wherein said methods involve the measurement of a level of IL-6 and/or IL-10.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*